BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 15108350)

  • 1. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
    Rikiishi H; Shinohara F; Sato T; Sato Y; Suzuki M; Echigo S
    Int J Oncol; 2007 May; 30(5):1181-8. PubMed ID: 17390020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
    BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
    Kim MS; Blake M; Baek JH; Kohlhagen G; Pommier Y; Carrier F
    Cancer Res; 2003 Nov; 63(21):7291-300. PubMed ID: 14612526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
    Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
    Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
    Kelly WK; Marks PA
    Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects.
    Xu WS; Perez G; Ngo L; Gui CY; Marks PA
    Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
    Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
    Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
    Hsi LC; Xi X; Lotan R; Shureiqi I; Lippman SM
    Cancer Res; 2004 Dec; 64(23):8778-81. PubMed ID: 15574791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
    Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
    J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.